Research Highlights:
Embargoed until 4 a.m. CT/5 a.m. ET, Monday, Nov. 2, 2026
DALLAS, Nov. 2, 2026 — In a survey of health clinics participating in a new initiative to improve care for cardiovascular-kidney-metabolic (CKM) syndrome , most sites reported conducting basic screening for heart, kidney and metabolic risks, however, far fewer are using newer guideline-recommended tools such as the CKM syndrome staging framework and the American Heart Association’s PREVENT ™ (Predicting Risk of cardiovascular EVENT) equations, according to new, preliminary research to be presented at the American Heart Association’s Scientific Sessions 2026 . The meeting, Nov. 6-9, in Chicago, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science.
The American Heart Association defines cardiovascular-kidney-metabolic syndrome as a multi-system health disorder due to connections between obesity , Type 2 diabetes , chronic kidney disease and heart disease . Nearly 90% of U.S. adults have at least one of the components of CKM syndrome, including high blood pressure, abnormal cholesterol, high blood glucose (sugar), excess weight, reduced kidney function or related heart conditions.
In 2025, the Association launched a learning collaborative and quality improvement initiative focused on the adoption of a CKM-coordinated care model in about 150 clinical sites across the U.S. Participating sites in the initial launch were selected based on factors such as the burden of CKM syndrome in their community, structural and societal influences, being in rural areas and by the health organization type.
All participating clinics were surveyed between Aug. 2025 – June 2026, to document a baseline of the implementation status of the initiative recommendations. A total of 97 clinical sites completed the standardized questionnaire.
“We found that most of the sites were actively screening patients for CKM risk factors and related conditions. Far fewer were using specifically recommended clinical assessment tools such as CKM syndrome staging and the PREVENT equations,” said lead author Chiadi Ndumele, M.D., Ph.D., M.H.S., FAHA, director of the Penn Center for Cardiometabolic Heath and Presidential Professor of Medicine at the University of Pennsylvania in Philadelphia. “However, that isn’t entirely surprising. These tools — and even CKM syndrome as a medical condition — embrace relatively new concepts just beginning to be adopted. This baseline is important because it shows we have opportunity to improve patient care as we help clinicians understand how to better incorporate these tools into their practices.”
What are the key findings of this survey?
“We see these conditions that define CKM syndrome clustering together — if a person has one condition, they’re more likely to be at risk for the others. Because they are so closely interconnected, we need to look at these all together, which led to this initiative,” Ndumele said. “The baseline assessments highlight areas most requiring targeted focus of implementation efforts to improve CKM syndrome care. Additionally, the details from this analysis inform the blueprint for adoption of evidence-based standards and a CKM model of care and provide evidence to support implementation. These findings could also pave the way for other healthcare sites and hospital systems seeking to improve care for patients with CKM syndrome within their clinical population.”
Ndumele said the CKM syndrome stages assessment and the PREVENT equations more closely identify specific risks and opportunities for improved care management.
There are four CKM syndrome stages, reflecting the typical evolution of CKM syndrome over time: 1.) Excess or dysfunctional fat which may accumulate around the liver, pancreas, heart and kidneys. 2.) Chronic kidney disease and/or metabolic risk factors 3.) Subclinical heart disease or high-risk equivalents and 4.) clinical heart disease. With early detection and preventive care to reduce progression along CKM syndrome stages, outcomes can improve substantially.
The American Heart Association’s PREVENT™ equations, based on contemporary data from more than 6.5 million diverse U.S. adults, have improved accuracy and are more generalizable to U.S. population than previous risk predicting tools. They can estimate 10-year and 30-year risk for cardiovascular disease development for people ages 30-79 without known heart disease, thereby helping to inform the use of preventive therapies.
Study details, background, design and limitations:
Study limitations include that although 150 clinical sites are included in the initiative, data from only 97 sites was available at the time of this analysis. The survey represents self-reported data from clinical sites, which is subject to recall bias and potential misclassification. Also clinical sites were chosen by initiative which is subject to selection bias. Ongoing assessments will provide a more comprehensive understanding of the implementation of CKM syndrome practices, as well as related barriers and opportunities, researchers said.
“We hope adoption of the newer, more comprehensive tools can help identify patients at higher risk and guide the effective provision of more whole-person care,” Ndumele said.
Authors, disclosures and funding sources are listed in the abstract.
Statements and conclusions of studies that are presented at the American Heart Association’s scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. Abstracts presented at the Association’s scientific meetings are not peer-reviewed, rather, they are curated by independent review panels and are considered based on the potential to add to the diversity of scientific issues and views discussed at the meeting. The findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.
The Association receives more than 85% of its revenue from sources other than corporations. These sources include contributions from individuals, foundations and estates, as well as investment earnings and revenue from the sale of our educational materials. Corporations (including pharmaceuticals, device manufacturers and other companies) also make donations to the Association. The Association has strict policies to prevent any donations from influencing its science content and policy positions. Overall financial information is available here .
Additional Resources:
###
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public’s health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on heart.org , Facebook , X or by calling 1-800-AHA-USA1.